Ephedrine sulfateAlternative Names: Akovaz; UMD 3 - Flamel Technologies; UMD#3 - Flamel Technologies; Unapproved marketed drug 3 - Flamel Technologies; Unapproved marketed drug#3 - Flamel Technologies; Undisclosed drug#3 - Flamel Technologies; Éclat #3
Latest Information Update: 09 Jan 2017
At a glance
- Originator Eclat Pharmaceuticals
- Developer Avadel Pharmaceuticals
- Class Antihypotensives; Decongestants; Propanolamines
- Mechanism of Action Alpha 1 adrenergic receptor agonists; Beta-adrenergic receptor agonists; Central nervous system modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypotension